New test predicts bowel cancer recurrence

A novel two-gene test targeting tumour DNA picks up twice as many cases of bowel cancer recurrence as the standard test, research shows.

Presence of two methylation DNA markers for the genes BCAT1 and IKZF1 was detected in almost 70% of patients with recurrent disease. By contrast, only 32% of people with recurrence tested positive for carcinoembryonic antigens (CEA), which is the most commonly used test for recurring colorectal disease.